From April 7 to 9, 2026, Royal proudly participated in the IPhEB Russia pharmaceutical exhibition, a leading platform bringing together top global companies and cutting-edge technologies in the industry.

During the event, Royal showcased its advanced capabilities in drug development and manufacturing and officially launched its star product — the Reference Listed Drug (RLD). As a reference listed drug, RLD is an innovative medicine approved through rigorous clinical trials and serves as the standard for bioequivalence studies and quality comparisons for generic drugs. By using RLD as a benchmark, generic drugs can ensure comparable efficacy and safety, providing patients with reliable treatment options.

RLD attracted significant attention from industry professionals at the exhibition, who recognized its high quality and regulatory compliance. This event further strengthened Royal’s presence in the international pharmaceutical market and highlighted the company’s ongoing commitment to innovation and high-quality drug development. Royal will continue to provide safe and effective pharmaceutical solutions for the global healthcare industry.